Dr. Peter A. Paximadis, MD

Dr. Paximadis practices at Corewell Health Lakeland Hospitals - Saint Joseph Hospital in Saint Joseph, Michigan, part of Corewell Health.

Dr. Paximadis' NPI, 1710147756, was assigned on June 12, 2008. Dr. Paximadis graduated from Wayne State University School Of Medicine in 2008. Dr. Paximadis holds Michigan license 4301092486.

Dr. Paximadis' primary practice is Corewell Health Lakeland Hospitals - Saint Joseph Hospital, at 1234 Napier Avenue, Saint Joseph, MI 49085 in Berrien County. The practice phone is (269) 983-8300.

Dr. Paximadis' primary practice is Corewell Health Lakeland Hospitals - Saint Joseph Hospital in Saint Joseph, Michigan, part of Corewell Health. Dr. Paximadis is also affiliated with Corewell Health Watervliet Hospital. The medical group on file is Corewell Health Medical Group South. Dmand AI also links Dr. Paximadis to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Paximadis practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Paximadis' primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Paximadis is board certified in radiation oncology by the American Board of Radiology. Dr. Paximadis is licensed in Michigan.

Dmand AI lists bladder cancer radiation, bone cancer radiation, breast cancer radiation, cancer radiation-upper GI, colorectal cancer radiation, head & neck cancer radiation, lung cancer radiation and prostate cancer radiation among the conditions Dr. Paximadis treats.

CMS data shows 1,735 Medicare services from Dr. Paximadis across 17 procedure codes in 2024, for 231 Medicare patients. Medicare paid $125,253 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 231 Medicare patients who saw Dr. Paximadis in 2024. The largest group is 65 to 74, with 96 patients. 75% of them have cancer, and 74% have high blood pressure. 12% are also on Medicaid. Their average risk score is 1.58, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Paximadis' median patient age at 72, with 47% women.

In 2024, Dr. Paximadis wrote 228 Medicare Part D claims for 81 patients. 97% of them were for generic drugs. CMS names the drug for 131 of them, across 3 drugs with 11 or more claims each, at $4,893 in total drug cost. In 2023, CMS named 99 claims across 3 drugs.

Dr. Paximadis accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 31 papers to Dr. Paximadis, published from 2011 to 2025. 2021 was the busiest year, with 4. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Radiotherapy Dosage. Dr. Paximadis has published most often in Pract Radiat Oncol. Dr. Paximadis' most frequent co-authors are Michael Matthew Dominello, DO, Shruti Jolly, MD and Thomas Pence Boike, MD.

Dmand AI links Dr. Paximadis to 3 clinical trials. 1 is still active or recruiting. Conditions studied include Adenocarcinoma, Bronchiolo-Alveolar, Pancreatic Intraductal Neoplasms and Adenocarcinoma of Lung.

CMS Open Payments shows 9 general payments to Dr. Paximadis from 8 drug and device companies from 2017 to 2025. Travel and lodging make up the largest share, 71% of the total. Carl Zeiss Meditec, Inc. paid the most, $552.

Dr. Paximadis graduated from Wayne State University School Of Medicine in 2008.

Dr. Paximadis is in network with 13 carriers, including Aetna, Health Alliance Plan and Priority Health. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.